葆元-Corporate-Presentation-January-2025-_vJPM_vF.pdf

《葆元-Corporate-Presentation-January-2025-_vJPM_vF.pdf》由会员分享，可在线阅读，更多相关《葆元-Corporate-Presentation-January-2025-_vJPM_vF.pdf（27页珍藏版）》请在三个皮匠报告上搜索。

1、DRIVEN BY SCIENCE,FOCUSED ON LIFEDavid Hung,M.D.Founder,President,&CEOJ.P.Morgan Healthcare ConferenceJanuary 2025Forward looking statementsCertain statements included in this presentation(this“Presentation”)that are not historical facts are forward-looking statements for purposes of the safe harbor

2、 provisions under the United States Private Securities Litigation Reform Act of 1995.Forward-looking statements are sometimes accompanied by words such as“believe,”“may,”“will,”“estimate,”“continue,”“anticipate,”“intend,”“expect,”“should,”“would,”“plan,”“predict,”“potential,”“seem,”“seek,”“future,”“

3、outlook”and similar expressions that predict or indicate future events or trends or that are not statements of historical matters.These forward-looking statements include,but are not limited to,our expectations the timing of FDA approval and commercial launch,expectations and timing of establishing

4、a commercial organization,a full NDA approval for taletrectinib for the treatment of advanced ROS1+NSCLC(line agnostic),the potential for taletrectinib to become a new therapeutic option for ROS1+NSCLC,taletrectinibs and safusidenibs best-in-class therapeutic potential,potential therapeutic benefit

5、of Nuvation Bios product candidates and planning and advancement of clinical studies for such product candidates,sufficiency of Nuvation Bios current cash balance to support operations in the near term,clinical study design,or the potential of the DDC platform.These statements are based on various a

6、ssumptions,whether or not identified in this Presentation,and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance.These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ f